Go Pro
→ Here’s the stock symbol I’ve promised (From Stansberry Research) (Ad)tc pixel Free ONCSQ Stock Alerts

OncoSec Medical (ONCSQ) Competitors

Compare

ONCSQ vs. SXTPW, BFRIW, CINGW, CLVR, and CMRAW

Should you buy OncoSec Medical stock or one of its competitors? OncoSec Medical's main competitors and comparable companies include 60 Degrees Pharmaceuticals (SXTPW), Biofrontera (BFRIW), Cingulate (CINGW), Clever Leaves (CLVR), and Comera Life Sciences (CMRAW). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does OncoSec Medical compare to 60 Degrees Pharmaceuticals?

60 Degrees Pharmaceuticals (NASDAQ:SXTPW) and OncoSec Medical (NASDAQ:ONCSQ) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends.

60 Degrees Pharmaceuticals has higher revenue and earnings than OncoSec Medical.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
60 Degrees Pharmaceuticals$1.11MN/AN/AN/AN/A
OncoSec MedicalN/AN/A-$34.18M-$7.15N/A

Company Net Margins Return on Equity Return on Assets
60 Degrees PharmaceuticalsN/A N/A N/A
OncoSec Medical N/A N/A N/A

In the previous week, 60 Degrees Pharmaceuticals had 1 more articles in the media than OncoSec Medical. MarketBeat recorded 1 mentions for 60 Degrees Pharmaceuticals and 0 mentions for OncoSec Medical. 60 Degrees Pharmaceuticals' average media sentiment score of 1.82 beat OncoSec Medical's score of 0.00 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
60 Degrees Pharmaceuticals Very Positive
OncoSec Medical Neutral

Summary

60 Degrees Pharmaceuticals beats OncoSec Medical on 3 of the 3 factors compared between the two stocks.

How does OncoSec Medical compare to Biofrontera?

Biofrontera (NASDAQ:BFRIW) and OncoSec Medical (NASDAQ:ONCSQ) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, media sentiment, dividends and profitability.

Biofrontera has higher revenue and earnings than OncoSec Medical.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biofrontera$46.18MN/AN/AN/AN/A
OncoSec MedicalN/AN/A-$34.18M-$7.15N/A

Company Net Margins Return on Equity Return on Assets
BiofronteraN/A N/A N/A
OncoSec Medical N/A N/A N/A

In the previous week, Biofrontera had 1 more articles in the media than OncoSec Medical. MarketBeat recorded 1 mentions for Biofrontera and 0 mentions for OncoSec Medical. Biofrontera's average media sentiment score of 1.79 beat OncoSec Medical's score of 0.00 indicating that Biofrontera is being referred to more favorably in the media.

Company Overall Sentiment
Biofrontera Very Positive
OncoSec Medical Neutral

Summary

Biofrontera beats OncoSec Medical on 3 of the 3 factors compared between the two stocks.

How does OncoSec Medical compare to Cingulate?

OncoSec Medical (NASDAQ:ONCSQ) and Cingulate (NASDAQ:CINGW) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, media sentiment, analyst recommendations and profitability.

Company Net Margins Return on Equity Return on Assets
OncoSec MedicalN/A N/A N/A
Cingulate N/A N/A N/A

In the previous week, Cingulate had 1 more articles in the media than OncoSec Medical. MarketBeat recorded 1 mentions for Cingulate and 0 mentions for OncoSec Medical. Cingulate's average media sentiment score of 1.82 beat OncoSec Medical's score of 0.00 indicating that Cingulate is being referred to more favorably in the news media.

Company Overall Sentiment
OncoSec Medical Neutral
Cingulate Very Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OncoSec MedicalN/AN/A-$34.18M-$7.15N/A
CingulateN/AN/AN/AN/AN/A

Summary

Cingulate beats OncoSec Medical on 2 of the 2 factors compared between the two stocks.

How does OncoSec Medical compare to Clever Leaves?

OncoSec Medical (NASDAQ:ONCSQ) and Clever Leaves (NASDAQ:CLVR) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, risk, media sentiment, earnings and institutional ownership.

Clever Leaves has higher revenue and earnings than OncoSec Medical.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OncoSec MedicalN/AN/A-$34.18M-$7.15N/A
Clever Leaves$17.42M0.00-$17.90M-$9.66N/A

In the previous week, OncoSec Medical's average media sentiment score of 0.00 equaled Clever Leaves'average media sentiment score.

Company Overall Sentiment
OncoSec Medical Neutral
Clever Leaves Neutral

OncoSec Medical has a beta of -30.04, suggesting that its share price is 3,104% less volatile than the broader market. Comparatively, Clever Leaves has a beta of 3853.65, suggesting that its share price is 385,265% more volatile than the broader market.

6.9% of Clever Leaves shares are held by institutional investors. 1.3% of OncoSec Medical shares are held by company insiders. Comparatively, 8.2% of Clever Leaves shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Company Net Margins Return on Equity Return on Assets
OncoSec MedicalN/A N/A N/A
Clever Leaves N/A N/A N/A

Summary

Clever Leaves beats OncoSec Medical on 5 of the 7 factors compared between the two stocks.

How does OncoSec Medical compare to Comera Life Sciences?

Comera Life Sciences (NASDAQ:CMRAW) and OncoSec Medical (NASDAQ:ONCSQ) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, earnings and institutional ownership.

Comera Life Sciences has higher revenue and earnings than OncoSec Medical.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Comera Life Sciences$1.00MN/AN/AN/AN/A
OncoSec MedicalN/AN/A-$34.18M-$7.15N/A

Company Net Margins Return on Equity Return on Assets
Comera Life SciencesN/A N/A N/A
OncoSec Medical N/A N/A N/A

In the previous week, Comera Life Sciences' average media sentiment score of 0.00 equaled OncoSec Medical'saverage media sentiment score.

Company Overall Sentiment
Comera Life Sciences Neutral
OncoSec Medical Neutral

Summary

Comera Life Sciences beats OncoSec Medical on 1 of the 1 factors compared between the two stocks.

Get OncoSec Medical News Delivered to You Automatically

Sign up to receive the latest news and ratings for ONCSQ and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ONCSQ vs. The Competition

Export
MetricOncoSec MedicalPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market CapN/A$12.66B$7.34B$13.18B
Dividend YieldN/A2.62%2.52%14.03%
P/E Ratio0.00653.53214.7321.08
Price / SalesN/A758.21613.3683.45
Price / CashN/A15.2228.0235.00
Price / BookN/A10.6310.536.44
Net Income-$34.18M$2.84B$3.50B$360.47M

OncoSec Medical Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ONCSQ
OncoSec Medical
N/AN/AN/AN/A$0.00N/AN/A40
SXTPW
60 Degrees Pharmaceuticals
N/A$0.04
flat		N/A-12.2%$0.00$1.11MN/A2
BFRIW
Biofrontera
N/A$0.02
flat		N/A-80.8%$0.00$46.18MN/A70
CINGW
Cingulate
N/A$0.01
-10.4%		N/AN/A$0.00N/AN/A20
CLVR
Clever Leaves
N/A$0.00
flat		N/AN/A$0.00$17.42MN/A560

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:ONCSQ) was last updated on 9/28/2026 by MarketBeat.com Staff.
From Our Partners
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...
Porter & Company | Sponsoredtc pixel
Management just bought 2.8 million shares
Management just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...
Monument Traders Alliance | Sponsoredtc pixel
This AI Stock Reminds One Analyst of Early Nvidia
Jeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...
Brownstone Research | Sponsoredtc pixel
Elon Musk’s Hushed FCC Filing. Dec 8th.
Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...
Paradigm Press | Sponsoredtc pixel
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
"How Much Can I Actually Spend Each Year With $2.5M Saved?"
Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...
SmartAsset | Sponsoredtc pixel
Major Buy Alert Issued for September 30th
Keith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...
TradeSmith | Sponsoredtc pixel